Skip to main content
Equibles
CHRS logo

CHRS

Coherus Oncology, Inc.
$1.67 +0.11 (+7.05%) At close · Jul 7
Market Cap
$254.51M
Shares
154,249,900

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.67 Open$1.56 Day$1.53–1.71 52W$0.73–2.62 Avg vol 30d976K Short int25.6M · 16.6% float · 33.4d Short vol24% Last earningsMay 11, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 11
Equibles Rating blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 16.1 · calm Equity put/call 0.69
Technical
price trend
Buy
50 / 200-day cross Death cross
Price vs 200-day avg +3%
above
Price vs 50-day avg +6%
above
RSI (14) 62
neutral
MACD trend Positive
52-week position 50%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +15%
trailing
6-month return +1%
trailing
YTD return +18%
this year
Relative strength −6%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) Death cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Distributing
3 of 156 funds reported for Jun 30 · net -487 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
16.62% of float · ▼ -8.0% MoM · 33.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
156 holders — mid 3-yr range
Squeeze score 80
high risk · 0–100
Fundamentals
Strong
Revenue growth −100%
Y/Y
EPS growth +472%
Y/Y
Free cash flow $-138.8M
Valuation P/E 1
below peers
Balance sheet $15.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 82%
annualized · 1-yr
Max drawdown −46%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next
Next earnings call
Aug 8, 2026 Est · unconfirmed · in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 11, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 3
      50 / 200-day cross
      Death cross Bearish
      Price vs 200-day avg
      +3% Bullish
      Price vs 50-day avg
      +6% Bullish
      RSI (14)
      62 Neutral
      MACD trend
      Positive Bullish
      52-week position
      50% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) Death cross
      50d $2 › 200d $2 — 200d above 50d
      Institutional flow Distributing
      3 of 156 funds reported for Jun 30 · net -487 sh shares
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      16.62% of float · ▼ -8.0% MoM · 33.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      156 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $1 Now $2 · 50% 52-wk high $3
      vs 200-day avg +3% vs 50-day avg +6% 50-day below 200-day death cross

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      CHRS
      Coherus Oncology, Inc.
      this stock
      		$254.51M +17.6% -100.0% 1.0 16.6%
      ONC
      BeOne Medicines Ltd.
      		 $446.53B +1.7% +22179.2% 908.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $132.55B +15.2% +46.2% 31.0 1.8%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $70.90B -12.3% +20.8% 16.5 3.2%
      ARGX
      Argenx SE
      		 $57.49B +9.4% — — 2.4%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      156
      % held
      38.2%
      Reported
      3 of 156
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      114
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      25.6M
      Days to cover
      33.4d
      Change
      -2.2M sh
      View
      Short Volume
      Short vol %
      24%
      As of
      Jul 7, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      94.1K
      Value
      $133.7K
      As of
      Jun 10, 2026
      View
      Off-Exchange
      Off-exchange %
      49.4%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Shri Thanedar
      Amount
      $15.0K–$50.0K
      Traded
      Jan 23, 2023
      View
      Financials
      Financials
      Revenue (FY)
      $0
      Net income (FY)
      $168.0M
      EPS diluted
      $1.43
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Jun 30, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $449.8K
      Shares
      223.1K
      Filed
      Nov 22, 2023
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jun 4, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      CHRS +15.2% +15.2% +1.2% +19.3% +17.6%
      SPY +0.9% +1.4% +7.6% +0.1% +9.7%
      vs SPY +14.3% +13.8% -6.4% +19.2% +8.0%
      Key facts CIK 1512762 CUSIP 19249H103 13F (30d) 4 filings 3 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)